{"id":87078,"date":"2025-11-24T08:18:43","date_gmt":"2025-11-24T15:18:43","guid":{"rendered":"https:\/\/www.uchealth.org\/today\/?p=87078"},"modified":"2025-11-25T07:15:22","modified_gmt":"2025-11-25T14:15:22","slug":"zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient","status":"publish","type":"post","link":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/","title":{"rendered":"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient"},"content":{"rendered":"
<\/div>
\"Colin
Colin Kiesel on his backyard mini half pipe as wife Natasha watches with son Will, 4. \u201cTo see how far he’s come is incredible,\u201d Natasha said. After Colin’s cancer diagnosis, Natasha contacted a friend in California with her idea of building a mini half pipe in their backyard. Several longtime California skateboard friends raised money to buy the materials. Three friends drove it out from California, surprised Colin and built the mini half-pipe. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

A new drug is providing hope to a handful of pancreatic cancer patients, including one young dad who was only 32 when doctors diagnosed him with stage 4 primary pancreatic adenocarcinoma in early 2024.<\/p>\n

The drug works for about one in 100 patients diagnosed with pancreatic cancer, but for some patients with tumors fueled by a genetic quirk called an NRG1 fusion<\/a>, zenocutuzumab (Bizengri) is having a profound impact.<\/p>\n

Colin Kiesel, 34, counts himself among the patients who are responding to zenocutuzumab.<\/p>\n

\"Colin
Colin got his first skateboard as a 7-year-old. When friends learned that Colin was facing a frightening cancer diagnosis, they teamed up to get him a mini half-pipe for his back yard. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

Kiesel had been dealing with a lingering respiratory crud that seemed to be sapping his energy for months \u2014 probably a bug his two-year-old son Will had brought home from daycare, he figured. Plus, a busy travel schedule to customers and conventions as the national sales manager for an apparel brand took him away from Will and wife Natasha about every week and provided little chance to recover.<\/p>\n

A day on the slopes of Steamboat proved pivotal. The expert snowboarder who typically rode steeps, bumps and rails from first chair to last found his legs trembling after just a few turns. An overwhelming sense of weakness snuffed out the usual exhilaration the mountain typically delivered. He also felt pain in his upper abdomen when he hit bumps. A visit to the doctor led to one with an oncologist, who delivered the unfathomable diagnosis: he had advanced cancer, and it was one of the worst kinds.<\/p>\n

The five-year survival rate<\/a> for stage 4 pancreatic cancer \u2014 that is, cancer that has spread beyond surrounding lymph nodes, as Kiesel\u2019s had \u2014 is just 3.2%.<\/p>\n

He was in rough shape. Tumors had infiltrated his liver. The surrounding lymph nodes were cancerous and enlarged, fluid accumulated in his pelvis, and the 5-foot-10-inch Kiesel\u2019s weight had plunged from 145 pounds to about 120.<\/p>\n

\u201cJust reading my son a couple of pages of a book was more than I could handle,\u201d Kiesel said.<\/p>\n

\"Colin,
Colin, Natasha, and Will at home in Erie with their Catahoula Leopard mix, Akeela. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

Chemotherapy is still the first-line treatment for metastatic pancreatic cancer<\/strong><\/h2>\n

Dr. Christopher Lieu<\/a>, a medical oncologist and professor<\/a> specializing in gastrointestinal cancers with the University of Colorado School of Medicine<\/a>, ordered a tumor biopsy and noted the NRG1 fusion.<\/p>\n

NRG1 fusions are a genetic trait that drives cancer-cell proliferation. Just 0.4% to 1.6% of pancreatic cancer patients have an NRG1 fusion, Lieu says, and, until recently, knowledge of it had no practical utility for patients. But a clinical trial was testing a drug developed by Netherlands-based Merus N.V., and early returns were promising. To join the trial, though, the cancer had to have progressed despite chemotherapy.<\/p>\n

Kiesel was doing chemotherapy, and the FOLFIRINOX<\/a> regimen was shrinking his tumors, making him ineligible for the trial. He got an infusion at UCHealth Cancer Care \u2013 Anschutz Medical Campus<\/a> every two weeks, followed by 48 hours on a fluorouracil pump at home. This would continue for 35 rounds, and, for more than a year, it kept the cancer in check.<\/p>\n

\"Kiesel
Kiesel added a \u201cSkate and Destroy Cancer\u201d sticker to his skateboard after he was diagnosed with Stage 4 pancreatic cancer two years ago. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

As with so many cancer patients, chemotherapy was tough on Kiesel. He felt sick for five or six days during and after the infusions, had a handful of days feeling more like his old self, and then the cycle repeated. Support from family and friends helped keep him going \u2014 especially early on, when the effects of chemotherapy layered over those of yet-unchecked cancer. His parents flew in from Florida and helped out for three months. Friends banded together to buy the avid skateboarder a mini half-pipe, packed the back of a sprinter van with the unassembled lumber, plywood and hardware and drove from California to the Kiesel home in Lakewood.<\/p>\n

\"Will
Will likes to slide down the curved wall with his parents. “Skateboarding teaches resilience,” Kiesel said. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

FDA approval of zenocutuzumab offers new hope<\/strong><\/h2>\n

By July 2025, Kiesel\u2019s pancreatic cancer was back on the offensive. Having now progressed on first-line chemotherapy, he would be eligible for the zenocutuzumab trial.\u00a0But he no longer needed a trial to access the\u00a0monoclonal antibody<\/a>: The U.S. Food and Drug Administration had\u00a0granted accelerated approval<\/a> for zenocutuzumab in December\u00a02024<\/span>\u00a0<\/a>for NRG1-fusion patients with metastatic pancreatic cancer or metastatic non-small cell lung cancer.<\/span>\u00a0The clinical trial<\/a> that led to approval found that the drug worked for 15 of the 36 patients with pancreatic cancer. Lieu prescribed it, and Kiesel became the first UCHealth patient to take zenocutuzumab.<\/p>\n

By early November, Kiesel was on his fifth infusion cycle of the drug. He\u2019s a stay-at-home dad now, delivering Will to and from school, doing the shopping and a lot of the cooking, and maintaining the household, now in Erie, while Natasha serves as breadwinner. He\u2019s back up to \u2014 or slightly above \u2014 his weight before diagnosis, his gym habit having added muscle.<\/p>\n

\"Colin
Colin offers a helpful push to his son, Will, 4, to begin his slow ride up the curved wall of the backyard mini halfpipe. “What do you do if you fall?” he asked Will later. \u201cGet up!\u201d Will said. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

\u201cWith this treatment, I\u2019m going to cook my family dinner, going to eat dinner with them, going to take my son to school in the morning, going to go work out tomorrow,\u201d Kiesel said. \u201cAnd I actually look forward to doing that stuff. On chemo, I would still try to do all that, but I\u2019d be white-knuckling it through everything.\u201d<\/p>\n

Lieu\u2019s take is that his patient looks great, and that assessment applies to more than just Kiesel\u2019s appearance. His scans show a stark retreat of tumors, and the CA 19-9 tumor markers<\/a> from his blood tests have gone from 1,500 units per milliliter when Lieu first met him to 34 \u2013 within the range of a healthy person\u2019s.<\/p>\n

\u201cI think the headline here would be, \u2018Right patient, right drug, right time,\u2019\u201d Lieu said.<\/p>\n

New pancreatic cancer treatment options coming <\/strong><\/h2>\n

How long zenocutuzumab will keep working for Kiesel, no one knows. Lieu says some patients will develop resistance; others could enjoy \u201clong, durable responses.\u201d But he sees zenocutuzumab as a promising early step toward what he is optimistic will be a wave of biomarker-directed therapies \u2014 that is, therapies aimed at specific genetic traits of a patient\u2019s tumors \u2014 for what has been a treatment-resistant, fast-growing, lethal cancer. One class of experimental therapies could have an especially big impact, he says: those that target the KRAS mutations<\/a> found in about 90% of pancreatic cancers (Kiesel\u2019s is among those that don\u2019t have it).<\/p>\n

Kiesel is doing his best to manage the fear and anxiety that come with each biweekly blood draw, each quarterly scan. He\u2019s sought out others, in person and online, who have found themselves in his shoes. Though few are as young as he is, it has helped him cope, he says.<\/p>\n

\u201cNo one\u2019s told me there\u2019s a chance of a cure,\u201d he said. \u201cSo, I try to stay as present as I can and make the most of each day.\u201d<\/p>\n

\"Colin
Colin Kiesel enjoys his backyard mini half pipe as Natasha and Will look on. A newly-approved drug, zenocutuzumab, is giving Kiesel hope, who has stage 4 primary pancreatic adenocarcinoma, and has kept him on his board. Photo by Sonya Doctorian, UCHealth.<\/figcaption><\/figure>\n

That means spending time with Natasha and, especially, Will. Father and son skateboard on the mini-halfpipe and at the local skate park; they ride bikes at the pump track. This winter, the two will head up past Nederland for Will to start snowboarding lessons at Eldora, so that, one day soon, he can follow his not-so-old man\u2019s tracks down the mountain.<\/p>\n

Kiesel is especially looking forward to that. In the meantime, he is savoring the principal gift this timely monoclonal antibody has given him \u2014 and that\u2019s time with his son.<\/p>\n

\u201cI\u2019m grateful that I can be here to take care of him,\u201d Kiesel said.<\/p>\n","protected":false},"excerpt":{"rendered":"

A new drug is providing hope to a handful of pancreatic cancer patients, including one young dad who was only 32 when doctors diagnosed him with stage 4 primary pancreatic adenocarcinoma in early 2024. The drug works for about one in 100 patients diagnosed with pancreatic cancer, but for some patients with tumors fueled by […]<\/p>\n","protected":false},"author":23,"featured_media":87089,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[5,7],"tags":[28,49,415],"class_list":["post-87078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-innovative-care","category-stories","tag-cancer-care-oncology","tag-cancer-treatment","tag-pancreatic-cancer"],"acf":[],"yoast_head":"\nNew drug, zenocutuzumab, offers hope for young pancreatic cancer patient - UCHealth Today<\/title>\n<meta name=\"description\" content=\"Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient\" \/>\n<meta property=\"og:description\" content=\"Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\" \/>\n<meta property=\"og:site_name\" content=\"UCHealth Today\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/uchealthorg\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T15:18:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T14:15:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.jpg\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Todd Neff, for UCHealth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uchealth\" \/>\n<meta name=\"twitter:site\" content=\"@uchealth\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Todd Neff, for UCHealth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\"},\"author\":{\"name\":\"Todd Neff, for UCHealth\",\"@id\":\"https:\/\/www.uchealth.org\/today\/#\/schema\/person\/da7733ff5562e48e55c027d111ee5911\"},\"headline\":\"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient\",\"datePublished\":\"2025-11-24T15:18:43+00:00\",\"dateModified\":\"2025-11-25T14:15:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\"},\"wordCount\":1510,\"publisher\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp\",\"keywords\":[\"Cancer care\",\"Cancer treatment\",\"Pancreatic Cancer\"],\"articleSection\":[\"Innovative care\",\"Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\",\"url\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\",\"name\":\"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient - UCHealth Today\",\"isPartOf\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp\",\"datePublished\":\"2025-11-24T15:18:43+00:00\",\"dateModified\":\"2025-11-25T14:15:22+00:00\",\"description\":\"Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage\",\"url\":\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp\",\"contentUrl\":\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp\",\"width\":800,\"height\":541,\"caption\":\"Colin Kiesel on his backyard mini half pipe as wife Natasha watches with son Will, 4, on Sunday, Nov. 9. \u201cTo see how far he's come is incredible,\u201d she said. Natasha contacted a friend in California with her idea of building a mini half pipe in their backyard last year. Several longtime California skateboard friends raised money to buy the materials. Three friends drove it out from California, surprised her husband,and built it. Natasha said, \u201cI know how much skateboarding means to Colin.\u201d Photo by Sonya Doctorian, UCHealth.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.uchealth.org\/today\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.uchealth.org\/today\/#website\",\"url\":\"https:\/\/www.uchealth.org\/today\/\",\"name\":\"UCHealth Today\",\"description\":\"UCHealth Today\",\"publisher\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.uchealth.org\/today\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.uchealth.org\/today\/#organization\",\"name\":\"UCHealth\",\"url\":\"https:\/\/www.uchealth.org\/today\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.uchealth.org\/today\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2020\/04\/24135149\/UCHealth-square-logo-1000x1000-1.jpg\",\"contentUrl\":\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2020\/04\/24135149\/UCHealth-square-logo-1000x1000-1.jpg\",\"width\":1000,\"height\":1000,\"caption\":\"UCHealth\"},\"image\":{\"@id\":\"https:\/\/www.uchealth.org\/today\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/uchealthorg\/\",\"https:\/\/x.com\/uchealth\",\"https:\/\/www.instagram.com\/uchealth\/\",\"https:\/\/www.linkedin.com\/school\/14839\/\",\"https:\/\/www.pinterest.com\/uchealthorg\/\",\"https:\/\/www.youtube.com\/channel\/UC41SJI79yjZIe96OajzN22g\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.uchealth.org\/today\/#\/schema\/person\/da7733ff5562e48e55c027d111ee5911\",\"name\":\"Todd Neff, for UCHealth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g\",\"caption\":\"Todd Neff, for UCHealth\"},\"description\":\"Todd Neff has written hundreds of stories for University of Colorado Hospital and UCHealth. He covered science and the environment for the Daily Camera in Boulder, Colorado, and has taught narrative nonfiction at the University of Colorado, where he was a Ted Scripps Fellowship recipient in Environmental Journalism. He is author of \u201cA Beard Cut Short,\u201d a biography of a remarkable professor; \u201cThe Laser That\u2019s Changing the World,\u201d a history of lidar; and \u201cFrom Jars to the Stars,\u201d a history of Ball Aerospace.\",\"url\":\"https:\/\/www.uchealth.org\/today\/author\/tneff\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient - UCHealth Today","description":"Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/","og_locale":"en_US","og_type":"article","og_title":"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient","og_description":"Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.","og_url":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/","og_site_name":"UCHealth Today","article_publisher":"https:\/\/www.facebook.com\/uchealthorg\/","article_published_time":"2025-11-24T15:18:43+00:00","article_modified_time":"2025-11-25T14:15:22+00:00","og_image":[{"url":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.jpg","type":"image\/jpeg"}],"author":"Todd Neff, for UCHealth","twitter_card":"summary_large_image","twitter_creator":"@uchealth","twitter_site":"@uchealth","twitter_misc":{"Written by":"Todd Neff, for UCHealth","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#article","isPartOf":{"@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/"},"author":{"name":"Todd Neff, for UCHealth","@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/person\/da7733ff5562e48e55c027d111ee5911"},"headline":"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient","datePublished":"2025-11-24T15:18:43+00:00","dateModified":"2025-11-25T14:15:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/"},"wordCount":1510,"publisher":{"@id":"https:\/\/www.uchealth.org\/today\/#organization"},"image":{"@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage"},"thumbnailUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp","keywords":["Cancer care","Cancer treatment","Pancreatic Cancer"],"articleSection":["Innovative care","Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/","url":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/","name":"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient - UCHealth Today","isPartOf":{"@id":"https:\/\/www.uchealth.org\/today\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage"},"image":{"@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage"},"thumbnailUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp","datePublished":"2025-11-24T15:18:43+00:00","dateModified":"2025-11-25T14:15:22+00:00","description":"Zenocutuzumab (Bizengri) targets NRG1 fusion found in about 1% of pancreatic cancers. For Colin Kiesel, it was the right drug at the right time.","breadcrumb":{"@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#primaryimage","url":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp","contentUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2025\/11\/21092531\/8-Colin-Kiesel-half-pipe-shadowed-sd-web.webp","width":800,"height":541,"caption":"Colin Kiesel on his backyard mini half pipe as wife Natasha watches with son Will, 4, on Sunday, Nov. 9. \u201cTo see how far he's come is incredible,\u201d she said. Natasha contacted a friend in California with her idea of building a mini half pipe in their backyard last year. Several longtime California skateboard friends raised money to buy the materials. Three friends drove it out from California, surprised her husband,and built it. Natasha said, \u201cI know how much skateboarding means to Colin.\u201d Photo by Sonya Doctorian, UCHealth."},{"@type":"BreadcrumbList","@id":"https:\/\/www.uchealth.org\/today\/zenocutuzumab-bizengri-offers-hope-young-pancreatic-cancer-patient\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.uchealth.org\/today\/"},{"@type":"ListItem","position":2,"name":"New drug, zenocutuzumab, offers hope for young pancreatic cancer patient"}]},{"@type":"WebSite","@id":"https:\/\/www.uchealth.org\/today\/#website","url":"https:\/\/www.uchealth.org\/today\/","name":"UCHealth Today","description":"UCHealth Today","publisher":{"@id":"https:\/\/www.uchealth.org\/today\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.uchealth.org\/today\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.uchealth.org\/today\/#organization","name":"UCHealth","url":"https:\/\/www.uchealth.org\/today\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/logo\/image\/","url":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2020\/04\/24135149\/UCHealth-square-logo-1000x1000-1.jpg","contentUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2020\/04\/24135149\/UCHealth-square-logo-1000x1000-1.jpg","width":1000,"height":1000,"caption":"UCHealth"},"image":{"@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/uchealthorg\/","https:\/\/x.com\/uchealth","https:\/\/www.instagram.com\/uchealth\/","https:\/\/www.linkedin.com\/school\/14839\/","https:\/\/www.pinterest.com\/uchealthorg\/","https:\/\/www.youtube.com\/channel\/UC41SJI79yjZIe96OajzN22g"]},{"@type":"Person","@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/person\/da7733ff5562e48e55c027d111ee5911","name":"Todd Neff, for UCHealth","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g","caption":"Todd Neff, for UCHealth"},"description":"Todd Neff has written hundreds of stories for University of Colorado Hospital and UCHealth. He covered science and the environment for the Daily Camera in Boulder, Colorado, and has taught narrative nonfiction at the University of Colorado, where he was a Ted Scripps Fellowship recipient in Environmental Journalism. He is author of \u201cA Beard Cut Short,\u201d a biography of a remarkable professor; \u201cThe Laser That\u2019s Changing the World,\u201d a history of lidar; and \u201cFrom Jars to the Stars,\u201d a history of Ball Aerospace.","url":"https:\/\/www.uchealth.org\/today\/author\/tneff\/"}]}},"coauthors":[{"id":23,"name":"Todd Neff","link":"https:\/\/www.uchealth.org\/today\/author\/tneff\/"}],"_links":{"self":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts\/87078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/comments?post=87078"}],"version-history":[{"count":10,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts\/87078\/revisions"}],"predecessor-version":[{"id":87144,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts\/87078\/revisions\/87144"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/media\/87089"}],"wp:attachment":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/media?parent=87078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/categories?post=87078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/tags?post=87078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}